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Abstract  
Introduction The case fatality in aneurysmal subarachnoid hemorrhage (aSAH) is 50% due 
to the initial hemorrhage or subsequent complications like aneurysmal rebleed or delayed 
cerebral ischemia (DCI). One factor that might influence the initial brain damage or 
subsequent complications is the use of antiplatelet medication before the initial hemorrhage. 
The goal of this survey was to assess the different management options of patients with aSAH 
with antiplatelet use before the initial hemorrhage. 
Material and methods An anonymous survey of 11 multiple-choice questions about 
management of aSAH patients with antiplatelet use before the initial hemorrhage was 
distributed to the international panel of attendees of the European Association of 
Neurosurgical Societies (EANS) annual meeting in Venice, Italy at 1-5 October 2017.   
Results A total of 258 (54%) completed surveys were returned. In about 80%, the 
departments of neurosurgery and neurology were responsible for acute management of aSAH 
patients, whereas in 15% the intensive care unit. Department guidelines were present in 32%. 
In 65%, the responders always stop the antiplatelet agent at admission and in 4.3% are 
thrombocytes always transfused. When a guideline is present, the neurospecialists consider 
thrombocyte transfusion more often (83% vs. 65% p=0.02). 
Conclusion Our survey among mainly European neurosurgeons show that there is a 
significant variability in the management of aSAH patients who have been using antiplatelets 
before the initial hemorrhage. These findings emphasize the importance of the development of 
evidence-based guidelines for management of patients with aSAH and antiplatelet use before 
the initial hemorrhage. 
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1 Introduction 
In patients with aneurysmal subarachnoid hemorrhage (aSAH), many factors are known to 
influence initial hemorrhage severity, rebleed rate and delayed cerebral ischemia (DCI) (e.g. 
age, aneurysm size, history of hypertension, heavy alcohol consumption, cigarette smoking). 
Many of those factors have been investigated and assessed whether they improve functional 
outcome. (1) Unfortunately the results are disappointing and it seems that the complications 
are multifactorial. One factor that might influence the initial hemorrhage severity, rebleed rate 
and rate of DCI, is the use of antiplatelet agents before the initial hemorrhage.  
In patients younger than 60 the prehemorrhage use of antiplatelet agents does probably not 
increase the risk of poor outcome. (2) When antiplatelet agents are administered after the 
initial SAH, a trend towards better outcome was seen in a Cochrane review. (3) A large 
multicenter trial with early thrombocyte transfusion, however, could not confirm an 
improvement in poor outcome. (4) Although antiplatelet use probably increases the risk of 
rebleeds (3, 5), which might be reduced by acute thrombocyte transfusion, the risks of 
thrombocyte transfusion after aSAH has not been investigated. Results of the recent PATCH 
study (6), in which aSAH patients were excluded showed that patients with intracerebral 
hemorrhages have a higher case fatality rate after acute thrombocyte transfusion in patients 
with prehemorrhage antiplatelet agents use. This finding opened the discussion whether 
thrombocyte transfusion could be harmful to aSAH patients instead of beneficial.  
The topic regarding stopping antiplatelet agents and whether to transfuse thrombocytes in 
aSAH patients remains an issue of debate. We therefore developed a survey to assess how 
neurospecialists deal with aSAH patients who use antiplatelet agents before the initial 
hemorrhage.  
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2 Material and methods  
 
Survey development and distribution 
We developed an anonymous survey containing 11 multiple-choice questions (Figure 1) 
regarding management of aSAH patients who use antiplatelet agents before the initial 
hemorrhage. We included more general questions about specialist and the institution type: 
country, specialty, number of aSAH patients per year, treatment-leading department at the 
admission of the patient. Furthermore, we asked about the existence of a guideline for treating 
patients with aSAH who have been using antiplatelet agents before the initial hemorrhage and 
which treating specialist makes the decision to transfuse thrombocytes. Questions about 
stopping the antiplatelet agents and transfusion of thrombocytes, including clinical status of 
patients have also been asked.  
A paper version of this survey was distributed to the attendees of the annual meeting of the 
European Association of Neurosurgical Societies (EANS), which took place in Venice, Italy 
at 1-5 October 2017 and collected immediately after completing the survey.  
 
Data analysis 
Data were manually imported in a digital database (Statistical Package for the Social Science 
(SPSS) version 24 for Windows (IBM, Armonk, New York, USA). To simplify the 
comparison between answer options, we combined   questions that were not answered with 
“always” or “never”, into a group called “individualized decision”. The various results were 
reported as value or proportion (%). Descriptive statistics were used to analyze the collected 
data. Categorical data were analyzed using the chi-square test. Statistical significance was 
defined at p < 0.05.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
 
3 Results 
A total of 478 surveys were distributed, and 258 (54%) completed surveys were returned. The 
responders were distributed among 51 different countries, with the majority originating from 
Europe. Figure 2A shows the continental geographical distribution of responders whereas 
figure 2B shows the distribution of completed surveys among European countries. The 
baseline characteristics of 258 respondents to the survey are shown in Table 1. 
About half of the responders worked in hospitals where more than 50 aSAH patients were 
treated per year. The departments of neurosurgery and neurology were responsible for 
primary management of aSAH in about 80%, whereas in 15% the intensive care unit took care 
of it. Department guidelines regarding management of antiplatelet agents use in aSAH 
patients were present in 32%. No difference in the presence of a guideline was found between 
Western and Eastern Europe (32% versus 33%, respectively). Similarly, 30% of Asian 
clinicians and 35% of clinicians from other countries had hospital guidelines. Approximately 
two-thirds (65%) of all responders always stop the administration of antiplatelet agents at 
admission and 4.3 % always transfuse thrombocytes (Table 2).         
 
The rate of decision to stop the antiplatelet agent and/or transfuse thrombocytes was different 
between hospitals who had a guideline or not. Table 3 shows the crosstab with distribution of 
answers. Neurospecialists tend to stop antiplatelet agents more often in institutions who use 
guidelines (p = 0.06), whereas they transfuse thrombocytes significantly more often p = 0.02). 
Stopping the antiplatelet agents and acute transfusion of thrombocytes are based on an 
individualized decision in 39% and 79%, respectively. 
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4 Discussion 
This international survey, distributed at EANS Congress in Venice in October 2017, offers 
insights into the current practice of management of patients who use antiplatelet agents before 
aSAH. The majority (82%) of the responders were originating from Europe and 18% from 
non-European countries (Table 1). The results show that there is a large difference in 
management among institutions. This emphasizes the lack of evidence-based guidelines for 
managing antiplatelet agents and thrombocyte transfusion in aSAH patients.  
 
1.1 Importance of guidelines in clinical practice 
About one third (32.2%) of clinicians work in institutions in which guidelines are present for 
management of aSAH patients with antiplatelet use before the initial hemorrhage. No 
difference in geographical distribution regarding department guidelines was found. This 
confirms our suspicion that a lack of in-hospital guidelines is a general phenomenon. 
Furthermore, a lack of guidelines and agreement could lead to different management at the 
same department by different clinicians. The American Heart Association/American Stroke 
Association has published general guidelines for the management of aSAH. These guidelines 
offer a framework for treatment of aSAH patients and improve their outcome. (7) 
Remarkably, analyses of Gritti et al. (8) showed that written protocols for aSAH management 
were not consistently used across institutions. Our analysis showed an interesting 
phenomenon regarding stopping the antiplatelet agents and acute transfusion of thrombocytes. 
Namely, antiplatelet agents tend to be stopped more often if institutional guidelines are 
present and thrombocytes are transfused in acute phase after aSAH significantly more often. 
These findings suggest that guidelines help in clinical decision-making regarding rare but 
relevant situations. Nevertheless, the clinical impact of stopping antiplatelet agents or 
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transfusion of thrombocytes is still unclear because literature on outcome after aSAH with the 
prehemorrhage use of antiplatelet agents is scare and show conflicting results.   
 
4.2 Prehemorrhage use of antiplatelets 
Administration of antiplatelet agents after aSAH is not recommended according to the current 
literature. (3, 7, 9) However, there is no literature known that describe how to deal with 
patients who already used antiplatelet agents before the initial hemorrhage. The influence of  
use of antiplatelet agents before initial hemorrhage was reported by Kato et al.(2) who 
reported that antiplatelet use significantly improved prognosis, albeit only in patients younger 
than 60 years. Gross et al. (10) suggested a potential beneficial effect of aspirin in the setting 
of aSAH by weighing the risk of aneurysm rupture against its potential adverse effects on 
hemorrhage severity. Additionally, Konczalla et al. (11) concluded that use of antithrombotic 
medication was associated with a significantly worse outcome and a higher mortality rate 
after aneurysmal and non-aneurysmal SAH.   
 
4.3 Thrombocyte transfusion in intracerebral hemorrhage   
No studies are known that evaluated the safety and efficacy of thrombocyte transfusion in 
patients with aSAH. Some reasons to transfuse thrombocytes after aSAH in patients who use 
of antiplatelet agents before the initial hemorrhage might be a possible reduction of rebleeds, 
less intracerebral hemorrhage after insertion of external ventricular drain or less risk for 
diffuse bleeding and postoperative hemorrhage by microsurgical clipping. (3, 5) Thrombocyte 
transfusion may be associated with activation of an inflammatory response and therefore 
potential harmful effect on DCI, and effects of the increased production of cytokines 
associated with the thrombocyte transfusion.  
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Thrombocyte transfusion in patients with spontaneous intracerebral hemorrhage (ICH), 
however, has been studied. (12-15) Recently, the results of the randomized controlled PATCH 
trial, comparing thrombocyte transfusion versus standard care without thrombocyte 
transfusion, were published. (6) The results show that patients with spontaneous ICH had a 
higher case fatality rate when thrombocytes were acutely transfused. This study emphasized 
the harmful effect of thrombocyte transfusion in patient with spontaneous ICH. Although 
patients with aSAH were not included in the study it opened the discussion whether 
thrombocyte transfusion in aSAH could be harmful to patients instead of beneficial. Based on 
the current knowledge, however, no recommendation regarding thrombocyte transfusion can 
be given in patients with aSAH. 
As the current literature fails guidelines regarding acute thrombocyte transfusion in patients 
with antiplatelet use before the aSAH, it is not surprising that 79% of respondents to our 
survey make an individualized decision. Antiplatelet type, result of aggregation test, kind of 
treatment (surgical or endovascular) as well as presence of intracerebral and/or 
intraventricular hemorrhage appear to have an impact on the decision to transfuse or not.  
Transfusion of thrombocytes in acute phase after aSAH is decided interdisciplinary in 42%.  
This supports the importance  of interdisciplinary guidelines among specialists who treat 
aSAH patients in order to achieve the best treatment based on current available literature and 
individual experiences. In approximately one fourth (26%) the neurosurgeon decides to 
transfuse thrombocytes which is probably a result of the importance of optimal intraoperative 
coagulation. In the majority of cases the amount of thrombocyte transfusion depends on type 
of antiplatelet agent which again emphasizes the personalized and individualized treatment of 
these patients. 
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4.4 Dilemmas in surgical and interventional procedures 
The lack of evidence and guidelines for management of pre-event and pre-surgical use of 
antiplatelet agents is not just a neurosurgical dilemma - other disciplines have similar 
problems. The current literature is contradictory regarding the question whether to continue or 
discontinue antiplatelet agents in the perioperative period. The beneficial effect of antiplatelet 
agents, however, is well documented in secondary prevention of myocardial infarction or 
stroke in patients with ischemic heart and cerebrovascular disease. (16) Despite evidence of 
benefit in these patients, antiplatelet agents are often discontinued before surgery due to the 
risk of perioperative bleeding. (17) However, some recent publications recommend that 
aspirin should not be routinely stopped in the perioperative period in cardiac surgery and 
spinal surgery patients. (18-21)  
Intracranial surgery, in comparison to other non-cranial surgeries, is associated more often 
with severe complications due to postoperative hemorrhages and therefore coagulation need 
to be optimal. Interestingly, in patients undergoing craniotomy for a brain tumor perioperative 
low dose aspirin use was not associated with an increased risk of bleeding complications or 
need for surgical revision. (22) One study (23) showed that aspirin administration in patients 
with increased risk for endovascular complications significantly decreased the rate of 
periprocedural thromboembolic events.  The rate of intracranial hemorrhages was not 
increased. On the contrary, another recent study (24) investigated whether the benefit of 
endovascular treatment compared to neurosurgical clipping is influenced by use of antiplatelet 
agents after coiling. The results of this study do not support the assumption that antiplatelets 
during or after endovascular coiling improve outcome in patients with SAH.  
 
Lastly, it is important to be aware of the possible (extracranial) complications (e.g. ischemic 
heart infarct, re-stenosis of coronary stents or bypasses pulmonary embolism) after stopping 
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antiplatelet agents. Ischemic strokes and myocardial infarctions were seen more than twice as 
much as recurrent ICH over a median of 41 months in a large cohort study. (25) Additionally, 
a study performed in 13 German stroke centers found no increase in recurrent ICH using 
antiplatelet agents versus no antithrombotic medication. (26) These data emphasize the 
importance of considering not only the intracranial but also the cardiac risks to decide 
whether to stop antiplatelet agents. 
 
 
4.1 Limitations 
Our survey has several limitations, particularly with regard to responder bias and 
generalizability. First, the survey was distributed to participants of the EANS congress in 
Venice and therefore the results more or less show the current European practice and might 
not be generalized globally because of the small number of responders from non-European 
countries. Second, responses were voluntary and could lead to a selection bias for people with 
a particular interest and/or knowledge in these issues. Furthermore, some limitations are due 
to the survey design: the working institution and training level (resident vs. attending) of 
respondents were not asked.  
 
5 Conclusion 
Our survey showthat there is a significant variability in management of aSAH patients who 
use antiplatelet agents before the initial hemorrhage. The presence of an in-hospital guideline 
appears to influence the decision of stopping the antiplatelet agents or to transfuse 
thrombocytes. Current literature is inconclusive regarding management of patients who use 
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antiplatelet agents before aSAH and therefore optimal management is unclear. These findings 
emphasize the importance of the development of evidence-based guidelines and the need for 
randomized clinical trials in patients with aSAH and use of antiplatelet agents before the 
initial hemorrhage. 
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Figure caption: 
Figure 1: Survey questions 
Figure 2: A.Distribution of completed surveys among continents. B. Distribution of numbers 
of completed surveys among European countries. 
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Tables 
Table 1 Baseline characteristics of 258 respondents to the survey 
 Number of respondents (%) 
Continent  
Western Europe* 151 (58.5) 
Eastern Europe* 60 (23.3) 
Asia 24 (9.3) 
Other 23 (8.9) 
Speciality  
Neurosurgery 254 (98.4) 
Other 4 (1.6) 
Number of aSAH treated in the hospital per year  
<25 40 (15.5) 
25-50 87 (33.7) 
50-100 84 (32.6) 
>100 47 (18.2) 
Department which is primary responsible for aSAH treatment  
Neurosurgery 184 (71.3) 
Neurology 21 (8.1) 
Intensive care 38 (14.7) 
Other 15 (5.9) 
Guidelines for treating patients with aSAH who have been using 
antiplatelet agents before onset of hemorrhage 
 
Yes 83 (32.2) 
No 175 (67.8) 
*Boarder between countries of Western and Eastern Europe was chosen according to historical and 
political statement. (31) Scandinavian countries belong to Western Europe, Baltic countries to Eastern 
Europe. Russia and Turkey as Euro-Asian countries were added to Eastern Europe.  
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Table 2 Results of survey 
 Number of respondents (%) 
Stopping administration of platelet agents  
Never 9 (3.5) 
Always 167 (64.7) 
individualized decision                                                                                       82 (31.8) 
depends on antiplatelet type                                                                33 (12.8) 
if surgical treatment is indicated                                                         31 (12.0) 
if surgical or endovascular treatment is indicated                                7 (2.7) 
if ICH or IVH is present                                                                       4 (1.6) 
if surgical treatment and ICH or IVH is present                                   7 (2.7) 
Thrombocyte transfusion  
Never 75 (29.1) 
Always 11 (4.3) 
individualized decision                                                                                        172 (66.6) 
depends on antiplatelet type                                                                 31 (12.0)                                              
depends on aggregation test                                                                 51 (19.8) 
if surgical treatment is indicated                                                          66 (25.6) 
if surgical or endovascular treatment is indicated                                11 (4.3) 
if ICH or IVH is present                                                                       5 (1.9) 
if surgical treatment and ICH or IVH is present                                   8 (3.1)                                                                   
Amount of thrombocyte transfusion  
6 units 51 (19.8) 
12 or more units 13 (5.0) 
depends on type of antiplatelet agent 95 (36.8) 
not applicable 99 (38.4) 
Physician who decides to give thrombocyte transfusion  
Neurosurgeon 66 (25.6) 
(neuro)intensivist 23 (8.9) 
Anaesthesiologist 13 (5.0) 
after interdisciplinary discussion 108 (41.9) 
not applicable 48 (18.6) 
ICH: intracerebral hemorrhage, IVH: intraventricular hemorrhage 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
 
 
Table 3. Crosstab of stop of antiplatelet agents and thrombocyte transfusion data in 
comparison to in-hospital guideline 
Stop of antiplatelet agents 
                                                                                        
never always individualized decision  
Guideline    
Yes 1 (1%)  50 (60%) 32 (39%) 
No 8 (5%) 117(67%) 50 (29%) 
Thrombocyte transfusion 
 
never always individualized decision 
Guideline    
Yes 14 (17%) 3 (4%) 66 (79%) 
No 61 (35%) 8 (3.5%) 106 (61%) 
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Highlights 
 
 
• Significant variability in management of aSAH patients who use antiplatelet agents. 
• Stopping antiplatelet agents and/or thrombocyte transfusion is an issue of debate.  
• Studies show conflicting results and optimal management is unclear. 
• The presence of an in-hospital guideline appears to influence the decision.  
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Abbreviation list 
 
aSAH – aneurysmal subarachnoid hemorrhage 
DCI – delayed cerebral ischemia 
EANS – European Association of Neurosurgical Societies 
ICH – intracerebral hemorrhage  
 
